[{"id":"c2396d97-5dcb-4957-9af5-f11594ca099b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762888","created_at":"2021-02-21T13:52:25.450Z","updated_at":"2024-07-02T16:35:23.055Z","phase":"Phase 2","brief_title":"68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer","source_id_and_acronym":"NCT04762888","lead_sponsor":"Mayo Clinic","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 01/10/2025","primary_completion_date":" 01/10/2025","study_txt":" Completion: 07/07/2025","study_completion_date":" 07/07/2025","last_update_posted":"2024-01-18"},{"id":"3d49c2e9-c873-459f-87ad-3ce24139ce28","acronym":"","url":"https://clinicaltrials.gov/study/NCT05603559","created_at":"2022-11-02T14:56:59.974Z","updated_at":"2024-07-02T16:35:32.151Z","phase":"Phase 1","brief_title":"177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05603559","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-P17-087 • 177Lu-P17-088"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 09/05/2023","primary_completion_date":" 09/05/2023","study_txt":" Completion: 10/04/2023","study_completion_date":" 10/04/2023","last_update_posted":"2023-10-23"},{"id":"0295021c-f48f-4edd-aba8-66c9bb49d96c","acronym":"PER2PSMA","url":"https://clinicaltrials.gov/study/NCT05819606","created_at":"2023-04-19T19:07:12.665Z","updated_at":"2024-07-02T16:35:50.107Z","phase":"","brief_title":"Positron Emission Radiomics With PSMA Radioligands on Newly Diagnosed Prostate Cancer Patients","source_id_and_acronym":"NCT05819606 - PER2PSMA","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • FOLH1 overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • FOLH1 overexpression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/15/2023","start_date":" 04/15/2023","primary_txt":" Primary completion: 10/15/2023","primary_completion_date":" 10/15/2023","study_txt":" Completion: 04/15/2024","study_completion_date":" 04/15/2024","last_update_posted":"2023-04-19"},{"id":"9cbbdb17-3c67-4f8e-b5b1-c043d0ec52f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05613738","created_at":"2022-11-14T15:57:13.650Z","updated_at":"2024-07-02T16:36:00.556Z","phase":"","brief_title":"177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05613738","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-LNC1003"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/23/2022","start_date":" 11/23/2022","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 11/15/2023","study_completion_date":" 11/15/2023","last_update_posted":"2022-11-11"},{"id":"df0d9226-3a47-4f82-892f-731646017c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996602","created_at":"2021-08-09T13:53:09.588Z","updated_at":"2024-07-02T16:36:07.278Z","phase":"Phase 1","brief_title":"Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC","source_id_and_acronym":"NCT04996602","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/14/2019","start_date":" 01/14/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-15"},{"id":"024afde8-35f7-422f-a157-f42ce2f8352a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780075","created_at":"2021-01-19T17:18:08.502Z","updated_at":"2024-07-02T16:36:10.526Z","phase":"Phase 1","brief_title":"Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT03780075","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2018","start_date":" 04/15/2018","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-05-12"},{"id":"3acfad33-7f8e-413e-8f32-aeb29860f23c","acronym":"NALuPROST","url":"https://clinicaltrials.gov/study/NCT04297410","created_at":"2021-01-19T19:26:17.125Z","updated_at":"2024-07-02T16:36:49.114Z","phase":"","brief_title":"177Lu-PSMA-I\u0026T Prior to Radical Prostatectomy for Locally Advanced Disease","source_id_and_acronym":"NCT04297410 - NALuPROST","lead_sponsor":"Rabin Medical Center","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"],"overall_status":"Unknown status","enrollment":" Enrollment 5","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 11/20/2021","primary_completion_date":" 11/20/2021","study_txt":" Completion: 04/20/2022","study_completion_date":" 04/20/2022","last_update_posted":"2020-03-05"},{"id":"e82d918b-6cc4-42ac-9711-92f01b350bee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03403595","created_at":"2021-01-25T07:52:39.275Z","updated_at":"2024-07-02T16:37:14.724Z","phase":"Phase 1","brief_title":"177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT03403595","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2018-01-18"}]